Lumen Peptides
Third-Party Tested Purity ≥ 99% Same-Day Shipping Before 12PM EST US-Based Support

BPC-157 vs TB-500: How the Research Peptides Compare

BPC-157 vs TB-500 compared: pentadecapeptide vs thymosin beta-4 fragment, their research focuses, and why they are combined in the Wolverine Stack. For research use only.

BPC-157 and TB-500 are two of the most-studied peptides in tissue-repair research, and they are frequently compared — and combined. This guide explains how the published scientific literature treats each, how they differ, and why researchers often study them together. It is written for researchers and is not medical guidance.

Research-use note: Both compounds discussed here are supplied strictly for laboratory research. They are not supplements and not for human or animal consumption. Nothing below describes or endorses human use.

Two different molecules, two different mechanisms

  • BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a body-protection-compound sequence found in gastric juice. Research has focused on tendon, muscle, and gastrointestinal models.
  • TB-500 is a synthetic fragment related to thymosin beta-4, a naturally occurring actin-binding peptide. Research has focused on cell migration, angiogenesis, and wound-healing models.

The key conceptual difference: BPC-157 is studied largely around localized tissue and gut-lining research, while thymosin beta-4 (the basis of TB-500) is studied around actin regulation and cell motility.

Side-by-side comparison

Property BPC-157 TB-500
Peptide type 15-aa synthetic pentadecapeptide Synthetic thymosin beta-4 fragment
CAS number 137525-51-0 77591-33-4
Primary research focus Tendon, muscle, GI-tract models Actin binding, angiogenesis, wound models
Notable property Stable in gastric environments Promotes cell migration
Available individually? Yes — standalone In research blends (Wolverine Stack, KLOW)

Why researchers combine them

Because the two peptides are studied along complementary pathways, they are frequently paired in research protocols — most commonly in the Wolverine Stack, which contains both. The idea in the research literature is to examine localized tissue-repair signaling (BPC-157) alongside actin-mediated cell-migration signaling (thymosin beta-4) in parallel.

What the research has examined

  • BPC-157 — Chang et al. (J Appl Physiol, 2011) examined tendon fibroblast outgrowth and migration; see our full BPC-157 research guide.
  • TB-500 / thymosin beta-4 — Malinda et al. (1999) reported accelerated wound healing in animal models; Goldstein et al. (2010) reviewed it as a multifunctional tissue-repair peptide.

These findings describe research outcomes in laboratory models, not validated outcomes in humans.

For research use only

All products and information referenced here are intended strictly for laboratory and scientific research use only. They are not for human or animal consumption and are not drugs, foods, supplements, or medical devices. No statement here should be interpreted as medical advice.

Shop these research peptides

References

  1. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol. 2011. PubMed
  2. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. PubMed
  3. Goldstein AL, et al. Thymosin beta4: a multifunctional tissue repair and regeneration peptide. 2010. PubMed

One comment

Comments are closed.